Biostem U.S. Corporation Scientific and Medical Board of Advisors Member Appointed Chief of Cardiothoracic Surgery at St. Francis Hospital

CLEARWATER, FL--(Marketwire - August 02, 2012) - Biostem U.S., Corporation, (OTCQB: HAIR) (PINKSHEETS: HAIR) (Biostem, the Company), a fully reporting public company in the stem cell regenerative medicine sciences sector, Chief Executive Officer Dwight Brunoehler stated, "Dr. Prendergast is a very talented and very active clinical and research surgeon. Biostem is fortunate to have his guidance in our scientific and medical pursuits. He will be playing an ever increasingly important role in the company's future regarding the use of stem cells and regenerative medicine."

According to Dr. Prendergast, "The Robert Wood Johnson Medical School currently has several stem cell related projects including the use of stem cells to reduce the risk of kidney related dysfunction following cardiac surgery. As Biostem grows, I look forward to assisting in implementing the Company's stem cell regenerative medicine goals in multiple areas."

Dr. Prendergast is a clinical cardiothoracic surgeon, who performs 200-250 open-heart operations and 5 to 15 heart transplants each year. He is deeply involved in numerous clinical and research activities associated with stem cells and heart repair. He is presently Director of Cardiac Transplantation at Robert Wood Johnson University Hospital in New Brunswick, New Jersey, where he holds an Associate Professorship of Surgery at the University of Medicine and Dentistry of New Jersey. In addition to being an active participant in stem cell research program development and teaching medical students and residents, his other interests include medical research funding and humanitarian development of programs for Disabled American Veterans.

Dr. Prendergast received his undergraduate degrees in biophysics and psychology, as well as his medical degree, at Pennsylvania State University. His general surgery residency was for five years at the University of Massachusetts Medical School. His cardiothoracic surgery training was at the University of Southern California School of Medicine, including the Los Angeles County Medical Center. Subsequent fellowship training included pediatric cardiac surgery at Children's Hospital Los Angeles, along with thoracic transplant fellowships at University of Southern California in Los Angeles and at Temple University Hospital in Philadelphia. He spent three years at the University of Kansas establishing thoracic transplant programs until returning to Temple University Hospital as one of their staff heart and lung transplant surgeons. Subsequent to his time at Temple, he joined up with Newark Beth Israel/St. Barnabas Hospitals, where he assumed directorship as the Chief of Cardiac Transplantation and Mechanical Assistance.

About Biostem U.S. Corporation

Biostem U.S., Corporation (OTCQB: HAIR) is a fully reporting Nevada corporation with offices in Clearwater, Florida. Biostem U.S. is a technology licensing company with proprietary technology centered on providing hair re-growth using human stem cells. The company also intends to train and license selected physicians to provide Regenerative Cellular Therapy treatments to assist the body's natural approach to healing tendons, ligaments, joints and muscle injuries by using the patient's own stem cells. Biostem U.S. is seeking to expand its operations worldwide through licensing of its proprietary technology and acquisition of existing stem cell related facilities. The company's goal is to operate in the international biotech market, focusing on the rapidly growing regenerative medicine field, using ethically sourced adult stem cells to improve the quality and longevity of life for all mankind.

The company's Board of Directors is headed by Chairman, Scott Crutchfield, who also acts as Senior Vice President of World Wide Operations for Crocs, Inc. (NASDAQ: CROX) and includes Crocs, Inc. original member, Steve Beck.

For further information on Biostem U.S. Corporation can be obtained through www.biostemus.com or by contacting Fox Communications Group at 310-974-6821.